Repeating
nature
Medical Additive Manufacturing
Additive manufacturing enables patient-specific implants when fit, geometry, and lead time matter. Ambrocio develops implant designs and manufacturing solutions for medical implants, with the option to support point-of-care manufacturing in hospital environments when appropriate.
-
Hospitals and manufacturers use additive manufacturing for standardised and patient-specific implants, depending on clinical need and the chosen production model.
-
Our focus is manufacturing-ready implant design, including printability and post-processing considerations, to support consistent production outcomes.
We design patient-specific medical implants for additive manufacturing and support consistent production through manufacturing-oriented design. Where appropriate, our solutions can also support point-of-care manufacturing in hospitals. We prioritise clarity, repeatability, and clinical relevance..
Medical Additive Manufacturing / Patient-specific implants / Medical-grade PEEK / Bioactive glass S53P4
Company
-
Ambrocio Oy, a privately owned company established in July 2019, was created by a dedicated team of experts in biomedical engineering, clinical science, biomaterials, and industrial design.
Our mission is to enable reliable access to patient-specific implants by providing manufacturing-ready designs and scalable production options, including point-of-care when appropriate.
Technology
Our implants integrate two key components:
Component 1: Polyether-ether-ketone (PEEK)
High durability, proven biocompatibility, and an established clinical track record. Optionally enhanced with calcium phosphate additives (PEEK-BCP) for improved biocompatibility
Component 2: Bioactive Glass S53P4 (BG)
Promotes integration of both hard and soft tissues. FDA-approved for cranio-maxillofacial reconstruction and bone void filling. Demonstrated inhibition of bacterial growth across up to 50 clinically relevant bacterial strains.
Ambrocio Oy holds a unique proprietary technology platform for bone regeneration, forming the core of our implant solutions. This technology is supported by several key patents:
- Finnish Patent FI 126495 B (granted in 2017)
- U.S. Patent US-11382754-B2 (granted in July 2022)
- European Patent EP3370792B1 (granted in April 2020)
Additionally, our advanced Biobuild technology for implant reinforcement using functionalized spatial arrangement of continuous fibers through Additive Manufacturing are protected by:
- Finnish Patent FI 129657 (granted in July 2022)
- U.S. Patent Application US17/626,511 (pending)
- European Patent Application EP20757623.2 (pending)
To complete the full-circle product approach, from planning through to the implementation of neurosurgical implants, we are developing proprietary AI-assisted software for the automatic design of patient-specific, manufacturer-agnostic implants on-site at the hospitals. This enhances hospital control over implant planning, keeps sensitive data secure, and facilitates competitive manufacturer bidding directly through established medical platforms.
Contacts
Ambrocio Oy
Business ID: 3012287-7
Werstas, DataCity (Entrance A), Lemminkäisenkatu 14-18 (3rd floor), 20520 Turku, Finland
